Recommendations about add-on reimbursement for medical devices in France in April 2025

The French National Authority for Health (HAS) has released new recommendations regarding the registration of add-on reimbursement for medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the April 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Eleven favorable opinions were published concerning the registration of new devices or modifying conditions/indications for existing ones in the LPPR List. 

The evaluation process begins with assessing the clinical (actual) benefit (Service Attendu, SA), which is classified as either sufficient or insufficient. Only devices with a sufficient clinical benefit are eligible for inclusion in the LPPR. If deemed sufficient, the clinical added value (Amélioration du Service Attendu, ASA) is then graded from I (major) to V (absent) for the claimed indications, influencing pricing decisions.

Examples of CNEDiMTS recommendations regarding the registration in the LPPR List in April 2025:

Examples of medical devices recommended for LPPR inclusion in April 2025 include:

• Paclitaxel-coated balloon IN.PACT 018 by Medtronic (application for registration; sufficient actual benefit; level V clinical added value compared to IN.PACT ADMIRAL);
• Rechargeable deep brain stimulation system VERCISE GENUS R16 by Boston Scientific (application for modification of conditions and renewal of registration; sufficient actual benefit; level V clinical added value compared to rechargeable deep brain stimulation systems listed on the LPPR for the selected indication);
• MINIMED 780G SYSTEM combined with the SIMPLERA SYNC continuous interstitial glucose sensor by Medtronic (application for registration; sufficient actual benefit; level V clinical added value compared to those systems specified in the CNEDiMTS opinion of 23.07.2024 on semi-closed loop systems: Other semi-closed loop systems registered on the LPPR).

Recommendations were also made regarding other neuromodulation devices and medical aids.

See the details in French here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.